SRZN vs. INKT, TARA, ACHL, PLUR, NKGN, CRTX, ESLA, SABS, BCLI, and QNCX
Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), Pluri (PLUR), NKGen Biotech (NKGN), Cortexyme (CRTX), Estrella Immunopharma (ESLA), SAB Biotherapeutics (SABS), Brainstorm Cell Therapeutics (BCLI), and Quince Therapeutics (QNCX). These companies are all part of the "medical" sector.
Surrozen (NASDAQ:SRZN) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
In the previous week, MiNK Therapeutics had 3 more articles in the media than Surrozen. MarketBeat recorded 8 mentions for MiNK Therapeutics and 5 mentions for Surrozen. Surrozen's average media sentiment score of 1.11 beat MiNK Therapeutics' score of 0.22 indicating that Surrozen is being referred to more favorably in the media.
Surrozen has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500.
66.6% of Surrozen shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 43.5% of Surrozen shares are held by insiders. Comparatively, 17.8% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
MiNK Therapeutics has a consensus target price of $9.00, indicating a potential upside of 703.57%. Given MiNK Therapeutics' higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Surrozen.
MiNK Therapeutics has lower revenue, but higher earnings than Surrozen.
MiNK Therapeutics received 8 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 68.75% of users gave MiNK Therapeutics an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
MiNK Therapeutics' return on equity of 0.00% beat Surrozen's return on equity.
Summary
MiNK Therapeutics beats Surrozen on 7 of the 13 factors compared between the two stocks.
Get Surrozen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surrozen Competitors List
Related Companies and Tools
